Eli Lilly is experiencing strong growth from its weight loss drugs, but investors are concerned about tariffs on drugs and weak data from its pipeline. The stock is cheaper but still trades at a premium valuation, despite sinking 18% this week. Revenue for the second quarter grew by 38%, driven by gains for its weight loss drugs. Net income also rose by 91%, but the stock dropped due to uncertainty over pharmaceutical tariffs and low data on a new weight-loss drug. Eli Lilly is guiding for just over $20 in earnings per share this year, with potential for further growth in the future.

Read more at Nasdaq: Why Eli Lilly Stock Sank 18% This Week